World Congresses of Gastroenterology, Vienna, September 1998
Symposium: Update on Hepatic Fibrosis
Guest Editor: Detlef Schuppan, Erlangen
Fibrosis and Altered Matrix DegradationArthur M.J.P.
University of Southampton, UK
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
- Cawston T: Matrix metalloproteinases and TIMPs: Properties and implications for the rheumatic diseases. Mol Med Today 1998;4:130–137.
- Iredale JP, Goddard S, Murphy G, Benyon RC, Arthur MJP: Tissue inhibitor of metalloproteinase-1 and interstitial collagenase expression in autoimmune chronic active hepatitis and activated human hepatic lipocytes. Clin Sci 1995;89:75–81.
- Iredale JP, Benyon RC, Arthur MJP, Ferris WF, Alcolado R, Winwood PJ, Clark N, Murphy G: Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology 1996;24:176–184.
- Vyas SK, Leyland H, Gentry J, Arthur MJP: Transin (stromelysin) is expressed in early rat lipocyte primary culture. Gastroenterology 1995;109:889–898.
- Arthur MJP, Friedman SL, Roll FJ, Bissell DM: Lipocytes from normal rat liver release a neutral metalloproteinase that degrades basement membrane (type IV) collagen. J Clin Invest 1989;84:1076–1085.
- Arthur MJP, Stanley A, Iredale JP, Rafferty JA, Hembry RM, Friedman SL: Secretion of 72-kDa type IV collagenase/gelatinase by cultured human lipocytes: Analysis of gene expression, protein synthesis and proteinase activity. Biochem J 1992;287:701–707.
Hovell CJ, Benyon RC, Baker JE, Arthur MJP: Membrane-type matrix metalloproteinase is produced by hepatic stellate cells. Hepatology 1995;22(suppl):369A.
- Winwood PJ, Schuppan D, Iredale JP, Kawser CA, Docherty AJP, Arthur MJP: Kupffer cell-derived 95-kDa type IV collagenase/gelatinase B: Characterisation and expression in cultured cells. Hepatology 1995;22:304–315.
- Fujiwara K, Sakai T, Oda T, Igarashi S: The presence of collagenase in Kupffer cells of the rat liver. Biochem Biophys Res Commun 1973;54:531–537.
- Theret N, Musso O, Lhelgoualch A, Clement B: Activation of matrix metalloproteinase-2 from hepatic stellate cells requires interactions with hepatocytes. Am J Pathol 1997;150:51–58.
- Herbst H, Heinrichs O, Schuppan D, Milani S, Stein H: Temporal and spatial patterns of transin/stromelysin RNA expression following toxic injury in rat liver. Virchows Arch B Cell Pathol 1991;60:295–300.
- Milani S, Herbst H, Schuppan D, Grappone SC, Pellegrini G, Pinzani M, Casini A, Calabro A, Ciancio G, Stefanini F, Burroughs AK, Surrenti C: Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol 1994;144:528–537.
- Takahara T, Furui K, Funaki J, Nakayama Y, Itoh H, Miyabayashi C, Sato H, Seiki M, Ooshima A, Watanabe A: Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology 1995;21:787–795.
Benyon RC, Hovell CJ, Arthur MJP: Gelatinase A (72-kDa type IV collagenase) is an autocrine proliferation factor for rat hepatic stellate cells. Hepatology 1997;26:186A.
- Perez-Tamayo R, Montfort I, Gonzalez E: Collagenolytic activity in experimental cirrhosis of the liver. Exp Mol Pathol 1987;47:300–308.
Maruyama K, Feinman L, Okazaki I, Lieber CS: Direct measurement of neutral collagenase activity in homogenates from baboon and human liver. Biochim Biophys Acta 1981;658:121–131.
- Maruyama K, Feinman L, Fainsilber Z, Nakano M, Okazaki I, Lieber CS: Mammalian collagenase increases in early alcoholic liver disease and decreases with cirrhosis. Life Sci 1982;30:1379–1384.
- Iredale JP, Murphy G, Hembry RM, Friedman SL, Arthur MJP: Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinase-1 (TIMP-1): Implications for regulation of matrix degradation in liver. J Clin Invest 1992;90:282–287.
- Kordula T, Guttgemann I, Rosejohn S, Roeb E, Osthues A, Tschesche H, Koj A, Heinrich PC, Graeve L: Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in human hepatoma cells (HepG2) – Up-regulation by interleukin-6 and transforming growth factor-beta 1. FEBS Lett 1992;313:143–147.
- Roeb E, Graeve L, Hoffmann R, Decker K, Edwards DR, Heinrich PC: Regulation of tissue inhibitor of metalloproteinase-1 gene expression by cytokines and dexamethasone in rat hepatocyte primary cultures. Hepatology 1993;18:1437–1442.
- Roeb E, Graeve L, Mullberg J, Matern S, Rosejohn S: TIMP-1 protein expression is stimulated by IL-1 beta and IL-6 in primary rat hepatocytes. FEBS Lett 1994;349:45–49.
- Benyon RC, Iredale JP, Goddard S, Winwood PJ, Arthur MJP: Expression of tissue inhibitor of metalloproteinase-1 and -2 in increased in fibrotic human liver. Gastroenterology 1996;110:821–831.
- Herbst H, Wege T, Milani S, Pellegrini G, Orzechowski HD, Bechstein WO, Neuhaus P, Gressner AM, Schuppan D: Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am J Pathol 1997;150:1647–1659.
Iredale JP, Northrop M, Vincent K, Mann DA, Arthur MJP: Possible role of apoptosis in regulating activated stellate cell numbers during liver injury. J Hepatol 1997;26:132.
Bahr MJ, Fowler AV, Arthur MJP, Mann DA: Cell type-specific regulation of the tissue inhibitor of metalloproteinase (TIMP)-1 gene promoter in hepatic stellate cells. J Hepatol 1997;26(suppl 1):66.
Mann DA, Bahr MJ, Vincent K, Arthur MJP: Induction of AP-1 DNA binding proteins during culture activation of hepatic stellate cells. Hepatology 1997;26:371A.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.